中国药业2025，Vol.34Issue(4)：124-128,5.DOI:10.3969/j.issn.1006-4931.2025.04.030
度普利尤单抗致银屑病相关不良反应文献分析
Literature Analysis of Psoriasis-Related Adverse Reactions Induced by Dupilumab
摘要
Abstract
Objective To provide a reference for the safe use of dupilumab in clinical practice.Methods Literature related to psoriasis and psoriatic-like skin lesions induced by dupilumab from March 2017 to November 2023 in the CNKI,WanFang,VIP,PubMed,Embase and Web of Science was collected,and the case characteristics were analyzed.Results A total of 33 articles were included,including 1 in Chinese and 32 in English;48 patients were involved,of which 41 had newly-diagnosed diseases,4 had previously aggravated diseases,and 3 were unknown.Among the patients,there were 27 males and 21 females,mainly aged 40-59 years(33.33%).Two cases had a personal/family history of psoriasis or both,39 cases had no the above medical history,and three cases of diseases were unknown;the most common medical history was allergic rhinitis(11 cases,22.92%);the main reason for medication was atopic dermatitis(44 cases,91.67%);the latency of adverse drug reactions(ADRs)was 10 d to 2.5 years,mainly occurring within six months after medication(34 cases,70.83%);the clinical classification was mainly plaque psoriasis(24 cases,50.00%);the lesion location were mainly distributed in the four limbs(30 cases,62.50%)and trunk(15 cases,31.25%).A total of 47 cases(97.92%)improved after withdrawal or dosage reduction and/or symptomatic treatment.Conclusion We should be paid to the psoriasis-related ADRs induced by dupilumab,especially for the patients with high-risk factors(male,40-59 years,history of psoriasis or family history,complicated with allergic rhinitis or asthma).During medication,it is necessary to strengthen monitoring of newly-developed or aggravated dermatitis,identify and diagnose it as early as possible,and give symptomatic treatment to ensure medication safety.关键词
度普利尤单抗/银屑病/药品不良反应/文献分析Key words
dupilumab/psoriasis/adverse drug reaction/literature analysis分类
医药卫生引用本文复制引用
张文,崔建蓉..度普利尤单抗致银屑病相关不良反应文献分析[J].中国药业,2025,34(4):124-128,5.基金项目
四川省成都市医学科研课题[2023573]. （）
